LENZ Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations And Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue:
License revenue	$5,000	$—	$5,000	$—
Total revenue	5,000	—	5,000	—
Operating expenses:
Research and development	9,061	6,945	14,879	17,482
Selling, general and administrative	12,796	7,407	23,909	12,958
Total operating expenses	21,857	14,352	38,788	30,440
Loss from operations	(16,857)	(14,352)	(33,788)	(30,440)
Other income:
Other income	199	1,635	188	287
Interest income	2,246	2,463	4,569	3,251
Total other income, net	2,445	4,098	4,757	3,538
Net loss before income taxes	(14,412)	(10,254)	(29,031)	(26,902)
Income tax expense	500	—	500	—
Net loss	$(14,912)	$(10,254)	$(29,531)	$(26,902)
Other comprehensive loss:
Unrealized loss on marketable securities	(85)	(61)	(158)	(68)
Comprehensive loss	$(14,997)	$(10,315)	$(29,689)	$(26,970)
Net loss per share, basic and diluted	$(0.53)	$(0.40)	$(1.06)	$(1.77)
Weighted-average common shares outstanding, basic and diluted (1)	28,079,071	25,608,594	27,804,112	15,163,103

(1)See Note 2 for further information on weighted-average common shares outstanding.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.